GSK will push five new drugs Novo expand smalutide Pfizer most want to improve is...

As soon as the J.MMorgan Health Conference opened, the chief executive of GlaxoSmithKline (GSK) held a press conference, and Alexion unveiled Ultomiris's latest plans in another hallWhat research and development progress and company trends did the major pharmaceutical companies such as Takeda, Novo Nordisk and Pfizer announce on the second day of the General Assembly?TakedaTakeda completed the deal to buy Shire, and Takeda chief executive Christophe Weber said the company had made great progress, with the two companies operating as a company and the company having completed the integration of talentIn terms of time and speed, this is a remarkable achievementTakeda also intends to achieve another achievement in 2020, which is to achieve the "carbon neutral" goal this yearCarbon neutrality refers to the total amount of greenhouse gas emissions produced directly or indirectly by enterprises over a certain period of time, through energy conservation and emission reduction and other forms, to offset their own carbon dioxide emissions, to achieve zero carbon dioxide emissionsAs a new form of environmental protection, it has been widely usedWith the verified amount of carbon offset, Takeda will have to offset 4.5 million tons of carbon'It's a financial commitment, and we've tried to reduce carbon emissions so takeit without changing financial targets, ' MrWeber saidBluebird Bio2019, Bluebird Bio CEO Nick Leschley spoke at the JPM conference about the company's four drug candidates that are struggling to address tough diseases such as sickle cells, cancer, and moreNow, Bluebird Bio is on the market with gene therapy Zynteglo, the first product the company has launched in Europe to treat blood transfusion-dependent beta thalassemiaTwo other FDA-approved drugs are scheduled to go on the market in Europe this yearfor Leschley, the submission itself is an important milestoneBut most importantly, Bluebird Has already obtained approval from u.Sdrug regulators for three products, which is a full validation of the company,Wall Street doesn't seem to think anything about it when it comes to evaluating PfizerThat's because they haven't seen revenue projections for the company's upcoming vaccines, including candidate drugs to prevent clostridium difficile, meningococcal disease and respiratory syncytial virus in pregnant women, chief executive Albert Bourla saidThere is also Pfizer's gene therapy program and most of its immuno-inflammatory drugsAs a result, Bourla believes there is a huge difference between "what analysts see" and "Pfizer sees Pfizer."But Pfizer is also partly responsible'For years, we've focused on research and development, but we haven't had a meeting with the media, investors, and analysts to share meaningful progress, and that's going to change in March,' Bourla saidLillyas a leading diabetes company, Lilly CEO Dave Ricks predicts that price pressures will remain the same overall as the types of drugs increase in people with diabetesalso noted that while Lilly Trulicity and Novo Nordisk's new oral Rybelsus (Sarulusino) are in the early stages of a battle with GLP-1 receptor agonists, he is confident that the company will use the anti-sugar drug for its weekly injectionsRicks argues that Novo Nordisk gained market share at the expense of Trulicity, but mainly at the expense of other GLP-1 products, including its own product, Victozamads Krogsgaard Thomsen, chief scientific officer ofand Nordand, and Marcus Schindler, senior vice president of global drug development, stressed that injection or oral use of saruotide shows hope beyond diabetes-only treatment The company is conducting prognostic tests on the drug for cardiovascular disease, diabetic retinopathy and chronic kidney disease at the same time , Novo Nordisk is further testing obese patients with non-alcoholic fatty hepatitis withdiabetes In addition, researchers outside the company have begun trials of the drug for use in Alzheimer's and Parkinson's disease Bob Bradway, chief executive of Amin , said that after buying the psoriasis drug Otezla from New Base for $13.4 billion in August last year, Amkin is now looking to add new indications to the blockbuster bomb in 2020 and roll it out on the international market the drug will help Amgen enrich its immunology products in the coming years, provided that Amgen continues to execute the program But Bradway said: "In the biopharmaceutical sector, the focus is on innovation, innovation, and re-innovation, and the principle of Amon is implementation, execution, and re-execution." "So it doesn't sound like a problem GSK
GSK has re-entered cancer treatment with the news of its $5.1 billion acquisition of Tesaro ahead of the 2019 JPM Healthcare Conference GSK CEO Emma Walmsley noted that the deal not only brought in PARP inhibitor Zejula, but also highly skilled staff with deep expertise in oncology, covering research and development, regulatory, medical affairs and market access, and sales representatives Professional and sales knowledge will prepare for the launch of GSK's three oncology products in 2020 2019, GSK's existing products are adding new indications, such as Zejula for first-line ovarian cancer maintenance treatments, Trelegy for asthma treatment, challenging Lynparza in AstraZeneca and Mersadon Walmsley said GSK was very focused on building channels for the next wave of growth and expected to launch five new products by 2020 five products, including the long-lasting cabotegravir and rilpivirine portfolio, are expected to be successful this year, although the FDA responded to a full response letter in December 2019 delaying the launch of the portfolio alexion Alexion's efforts to support sales growth in the older drug Soliris through ultomiris, a new generation of long-lasting products for rare blood diseases, have seen patients expect more than expected of new drugs Alexion is not content to simply transfer the patient market to Ultomiris, but also wants to expand the market, planning to use the drug to treat amyotrophic lateral sclerosis Ludwig Hantson, chief executive of Alexion, said it was a high-risk, high-return scheme But it seems the company still wants to try references: 1, JPM to know, Day 2: GSK's rollout agenda, Alexion's longshot, bluebird's turkey-just and whoknows Pfizer?
2, JPM: With Tesaro staff and expertise in the mix, GSK gears up for 3 launches in 2020